In the last trading session, 6.2 million Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares changed hands as the company’s beta touched 1.05. With the company’s per share price at $3.56 changed hands at -$0.05 or -1.39% during last session, the market valuation stood at $1.17B. IOVA’s last price was a discount, traded about -299.72% off its 52-week high of $14.23. The share price had its 52-week low at $2.70, which suggests the last value was 24.16% up since then. When we look at Iovance Biotherapeutics Inc’s average trading volume, we note the 10-day average is 8.34 million shares, with the 3-month average coming to 9.80 million.
Analysts gave the Iovance Biotherapeutics Inc (IOVA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.31. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended IOVA as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Instantly IOVA was in red as seen at the end of in last trading. With action 10.90%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -51.89%, with the 5-day performance at 10.90% in the green. Looking at the short shares, we see there were 71.37 million shares sold at short interest cover period of 7.49 days.
The consensus price target for the stock as assigned by Wall Street analysts is 6, meaning bulls need an upside of 40.67% from its current market value. According to analyst projections, IOVA’s forecast low is 6 with 6 as the target high. To hit the forecast high, the stock’s price needs a -68.54% plunge from its current level, while the stock would need to soar -68.54% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 4.17%. The 2025 estimates are for Iovance Biotherapeutics Inc earnings to increase by 38.71%.
IOVA Dividends
Iovance Biotherapeutics Inc is expected to release its next quarterly earnings report on 2025-Feb-26.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.63% of Iovance Biotherapeutics Inc shares while 83.74% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 84.27%. There are 83.74% institutions holding the Iovance Biotherapeutics Inc stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 9.1113% of the shares, roughly 25.95 million IOVA shares worth $208.12 million.
PERCEPTIVE ADVISORS LLC holds the second largest percentage of outstanding shares, with 9.1052% or 25.93 million shares worth $207.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 8.61 shares estimated at $30.65 million under it, the former controlled 2.63% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.22% of the shares, roughly 7.28 shares worth around $25.93 million.
